SUPERNUS PHARMACEUTICALS, INC. Increase (Decrease) in Accrued Interest Receivable, Net
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Increase (Decrease) in Accrued Interest Receivable, Net of $10.00 thousand for the 9-month period ending 2014-09-30, per its 10-Q filed 2014-11-12.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet · last filed 2014-11-12
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accrued interest receivable, net for the quarter ending 2014-09-30 was -$3.00K, a 101.56% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accrued interest receivable, net for the quarter ending 2014-06-30 was -$140.00K, a 217.65% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accrued interest receivable, net for the quarter ending 2014-03-31 was $153.00K, a 1812.50% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accrued interest receivable, net for the quarter ending 2013-12-31 was -$500.00K, a 254.80% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accrued interest receivable, net for fiscal 2013 was -$181.00K, a 127.26% decline from fiscal 2012.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accrued interest receivable, net for fiscal 2012 was $664.00K.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accrued interest receivable, net for fiscal 2011 was -$114.00K.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accrued interest receivable, net for fiscal 2010 was -$220.00K.
| Period end | Increase (Decrease) in Accrued Interest Receivable, Net 3 month | Increase (Decrease) in Accrued Interest Receivable, Net 6 month | Increase (Decrease) in Accrued Interest Receivable, Net 9 month | Increase (Decrease) in Accrued Interest Receivable, Net 12 month |
|---|---|---|---|---|
| 2014-09-30 | -$3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | -$143.00K derived: sum of 2 quarters · filed 2014-11-12 | $10.00K 10-Q · filed 2014-11-12 | -$490.00K derived: sum of 4 quarters · filed 2014-11-12 |
| 2014-06-30 | -$140.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | $13.00K 10-Q · filed 2014-08-12 | -$487.00K derived: sum of 3 quarters · filed 2014-08-12 | -$295.00K derived: sum of 4 quarters · filed 2014-11-12 |
| 2014-03-31 | $153.00K 10-Q · filed 2014-05-13 | -$347.00K derived: sum of 2 quarters · filed 2014-05-13 | -$155.00K derived: sum of 3 quarters · filed 2014-11-12 | -$36.00K derived: sum of 4 quarters · filed 2014-11-12 |
| 2013-12-31 | -$500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-21 | -$308.00K derived: sum of 2 quarters · filed 2014-11-12 | -$189.00K derived: sum of 3 quarters · filed 2014-11-12 | -$181.00K 10-K · filed 2014-03-21 |
| 2013-09-30 | $192.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $311.00K derived: sum of 2 quarters · filed 2014-11-12 | $319.00K 10-Q · filed 2014-11-12 | $642.00K derived: sum of 4 quarters · filed 2014-11-12 |
| 2013-06-30 | $119.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | $127.00K 10-Q · filed 2014-08-12 | $450.00K derived: sum of 3 quarters · filed 2014-08-12 | |
| 2013-03-31 | $8.00K 10-Q · filed 2014-05-13 | $331.00K derived: sum of 2 quarters · filed 2014-05-13 | ||
| 2012-12-31 | $323.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-21 | $664.00K 10-K · filed 2014-03-21 | ||
| 2012-09-30 | $341.00K 10-Q · filed 2013-11-13 | |||
| 2011-12-31 | -$114.00K 10-K · filed 2014-03-21 | |||
| 2010-12-31 | -$220.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |